These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18519723)

  • 41. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals.
    Kim CH; Kang HY; Kim BR; Jeon H; Lee YC; Lee SH; Lee JC
    J Microbiol; 2016 Jan; 54(1):44-49. PubMed ID: 26727901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
    Ida T; Tsushima M; Ishii T; Atsumi K; Tamura A
    J Infect Chemother; 2002 Jun; 8(2):138-44. PubMed ID: 12111566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
    Hikida M; Terashima S; Sato Y; Okamoato R; Inoue M
    Jpn J Antibiot; 2001 Nov; 54(11):571-9. PubMed ID: 11828603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
    Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular typing and resistance mechanisms of carbapenem resistant Pseudomonas aeruginosa isolated from a Chinese surgical intensive care unit.
    Yi M; Wang P; Liu Y
    Chin Med J (Engl); 2014; 127(6):1071-6. PubMed ID: 24622437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems.
    Köhler T; Michea-Hamzehpour M; Epp SF; Pechere JC
    Antimicrob Agents Chemother; 1999 Feb; 43(2):424-7. PubMed ID: 9925552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of carbapenem resistance in non-metallo-beta-lactamase-producing clinical isolates of Pseudomonas aeruginosa from a Tunisian hospital.
    Hammami S; Ghozzi R; Burghoffer B; Arlet G; Redjeb S
    Pathol Biol (Paris); 2009; 57(7-8):530-5. PubMed ID: 18977099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis of J-111,347, a novel 1 beta-methylcarbapenem with broad-spectrum antibacterial activity.
    Imamura H; Ohtake N; Sakuraba S; Shimizu A; Yamada K; Morishima H
    Chem Pharm Bull (Tokyo); 2000 Feb; 48(2):310-1. PubMed ID: 10705531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Kamimura T; Tawara S; Matsumoto Y; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):99-119. PubMed ID: 8436564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations of porin, pumps, and penicillin-binding proteins in carbapenem resistant clinical isolates of Pseudomonas aeruginosa.
    Giske CG; Buarø L; Sundsfjord A; Wretlind B
    Microb Drug Resist; 2008 Mar; 14(1):23-30. PubMed ID: 18321207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations.
    Chalhoub H; Sáenz Y; Rodriguez-Villalobos H; Denis O; Kahl BC; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2016 Dec; 48(6):740-743. PubMed ID: 28128097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.
    Sumita Y; Fukasawa M
    J Antimicrob Chemother; 1995 Jul; 36(1):53-64. PubMed ID: 8537284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
    Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
    Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.
    Tanaka K; Mikamo H; Nakao K; Ichiishi T; Goto T; Yamagishi Y; Watanabe K
    Antimicrob Agents Chemother; 2009 Jan; 53(1):319-22. PubMed ID: 18955522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.